Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of etoposide and mitoxantrone hydrochloride when given together with cyclosporine and pravastatin sodium and to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia (AML). Cyclosporine may inhibit efflux of cancer drugs out of cancer cells and may thereby improve chemotherapy treatment for AML. Pravastatin sodium may stop the growth of cancer cells by blocking some of the nutrients needed for cell growth. Drugs used in chemotherapy, such as etoposide and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving cyclosporine together with pravastatin sodium, etoposide, and mitoxantrone hydrochloride may kill more cancer cells
Detailed description
PRIMARY OBJECTIVES: I. Determine the maximum tolerated doses of mitoxantrone (mitoxantrone hydrochloride) and etoposide in combination with pravastatin (pravastatin sodium) and cyclosporine. SECONDARY OBJECTIVES: I. Describe the complete remission (CR)/CR with incomplete peripheral blood count recovery (CRi) rate after up to 2 cycles of induction therapy. II. Describe the disease-free survival of patients that achieve CR/CRi. III. Estimate the frequency and severity of regimen-associated toxicities, along with 28-day mortality after start of study treatment. OUTLINE: This is a phase I/II, dose-escalation study of etoposide and mitoxantrone hydrochloride in combination with pravastatin sodium and cyclosporine. Patients receive cyclosporine intravenously (IV) continuously on days 5-9. Patients also receive pravastatin sodium orally (PO) every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 1 month.
Interventions
DRUGcyclosporine
Given IV
Given PO
DRUGmitoxantrone hydrochloride
Given IV
DRUGetoposide
Given IV
PROCEDUREbone marrow aspiration
Correlative studies
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treatment-related mortality (TRM) score =\< 9.2 as calculated with simplified model * Prior morphological diagnosis of AML according to the 2008 World Health Organization (WHO) diagnostic criteria; patients with biphenotypic AML are eligible; patients with acute promyelocytic leukemia with t(15;17)(q22;q12) and variants are ineligible * Relapsed/persistent disease as defined by International Working Group criteria; outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution; flow cytometric analysis of peripheral blood and/or bone marrow should be performed according to institutional practice guidelines * Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) are eligible if relapse occurs \> 180 days post-transplant provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents * Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, assessed at time of registration * Should be off any active therapy for AML with the exception of hydroxyurea or low-dose cytarabine (=\< 100 mg/m\^2) for at least 14 days prior to study registration unless patient has rapidly progressive disease, and all Grade 2-4 non-hematologic toxicities must have resolved * Bilirubin =\< 2 x Institutional Upper Limit of Normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 7 days prior to registration) * Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 2 x IULN unless elevation is thought to be due to hepatic infiltration by AML (assessed within 7 days prior to registration) * Serum creatinine =\< 1.5 x IULN (assessed within 7 days prior to registration) * Left ventricular ejection fraction \>= 40%, assessed within 28 days prior to registration, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other appropriate diagnostic modality, and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographical suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal * Patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) \> 100,000/uL can be treated with leukapheresis prior to enrollment * Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation * Ability to understand and the willingness to sign a written informed consent document; the consent can be obtained from a legally authorized representative if the patient is unable to provide informed consent
Exclusion criteria
* Diagnosis of another malignancy, unless the patient was diagnosed at least 2 years earlier and has been disease-free for at least 6 months following the completion of curative intent therapy with the following exceptions: * Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed * Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed * Refractory/relapsing blast crisis of chronic myelogenous leukemia (CML) * Known hypersensitivity to any study drug * Human immunodeficiency virus (HIV)-positive patients are excluded if their cluster of differentiation (CD)4 count is below 200 cells/uL or if they have active acquired immune deficiency syndrome (AIDS)-related complications, as these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy * Pregnancy or lactation; women of childbearing potential must undergo pregnancy test within 7 days prior to registration * Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting progressive signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) * Patients may not be receiving any other investigational agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium | After completion of first 2 courses, up to 22 weeks | Determine the doses of mitoxantrone and etoposide that, when combined with CSA and pravastatin, meet minimum standards for both efficacy and toxicity and have the highest efficacy rate among several mitoxantrone and etoposide doses. Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CR/CRi | After completion of first 2 courses, up to 22 weeks | Describe the disease-free survival of patients that achieve Complete Remission (CR)/CR with inadequate recovery of peripheral blood cell counts (CRi). Categorized according to criteria recommended by an International Working Group. |
| Disease-free Survival of Patients That Achieve CR/CRi | Up to 4.5 years | Describe the disease-free survival of patients that achieve CR/CRi. |
| Frequency and Severity of Regimen-associated Toxicities | At 28 days | Estimate the frequency and severity of regimen-associated toxicities, along with 28-day mortality after start of study treatment |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
cyclosporine: Given IV
pravastatin sodium: Given PO
mitoxantrone hydrochloride: Given IV
etoposide: Given IV
bone marrow aspiration: Correlative studies | 6 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 2 |
Baseline characteristics
| Characteristic | Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) |
|---|---|
| Age, Continuous | 51 years |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 6 / 6 |
| serious Total, serious adverse events | 5 / 6 |
Outcome results
Primary
Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium
Determine the doses of mitoxantrone and etoposide that, when combined with CSA and pravastatin, meet minimum standards for both efficacy and toxicity and have the highest efficacy rate among several mitoxantrone and etoposide doses. Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: After completion of first 2 courses, up to 22 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium | 0 doses tolerated |
Secondary
CR/CRi
Describe the disease-free survival of patients that achieve Complete Remission (CR)/CR with inadequate recovery of peripheral blood cell counts (CRi). Categorized according to criteria recommended by an International Working Group.
Time frame: After completion of first 2 courses, up to 22 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | CR/CRi | CR | 0 Participants |
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | CR/CRi | CRi | 0 Participants |
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | CR/CRi | CR/CRi not achieved | 6 Participants |
Secondary
Disease-free Survival of Patients That Achieve CR/CRi
Describe the disease-free survival of patients that achieve CR/CRi.
Time frame: Up to 4.5 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Disease-free Survival of Patients That Achieve CR/CRi | 0-6month survival of those achieving CR/CRi | 0 Participants |
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Disease-free Survival of Patients That Achieve CR/CRi | >6month survival of those achieving CR/CRi | 0 Participants |
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Disease-free Survival of Patients That Achieve CR/CRi | Participants who do not achieve CR/CRi | 6 Participants |
Secondary
Frequency and Severity of Regimen-associated Toxicities
Estimate the frequency and severity of regimen-associated toxicities, along with 28-day mortality after start of study treatment
Time frame: At 28 days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Frequency and Severity of Regimen-associated Toxicities | Early death (within 28 days) | 2 Participants |
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Frequency and Severity of Regimen-associated Toxicities | Experienced Dose-Limiting Toxicity | 1 Participants |
| Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo) | Frequency and Severity of Regimen-associated Toxicities | Persistent Disease | 3 Participants |